WuXi Biologics Receives EcoVadis Platinum Medal for Third Consecutive Year

Reuters
Yesterday
WuXi Biologics Receives EcoVadis Platinum Medal for Third Consecutive Year

WuXi Biologics (Cayman) Inc. has received a Platinum Medal from the EcoVadis Sustainability Rating for the third consecutive year. The company was ranked in the top 1% of more than 150,000 companies assessed globally. EcoVadis evaluates companies on environmental, labor and human rights, ethics, and sustainable procurement criteria. WuXi Biologics’ sustainability initiatives include Science Based Targets initiative (SBTi)-approved greenhouse gas emissions reduction targets and the release of a Green CRDMO White Paper detailing green innovation technologies and energy-saving measures. The company has also been recognized by other organizations for its environmental, social, and governance $(ESG)$ performance, including the MSCI AAA Rating, Dow Jones Sustainability Indices, CDP "A List" for Climate Change and Water Security, and inclusion in the FTSE4Good Index Series.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN83269) on February 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10